Ca2+-activated K+ channels mediate relaxation of forearm veins in chronic renal failure

Journal of Hypertension

Volumn 21, Issue 10, 2003, Pages 1927-1934

  Martinez León, Juan B ^a   Segarra, Gloria ^a   Medina, Pascual ^b   Vila, José M ^b   Lluch, Paloma ^b   Peiró, Marta ^b   Otero, Eduardo ^a   Lluch, Salvador ^b,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Endothelium derived relaxing factors; Potassium channels; Renal disease; Veins

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ACETYLCHOLINE; APAMIN; BARIUM; CALCIUM; CALCIUM CHANNEL; CHARYBDOTOXIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLIBENCLAMIDE; IBERIOTOXIN; INDOMETACIN; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; OUABAIN; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM IODIDE; TETRYLAMMONIUM CHLORIDE; 1H (1,2,4)OXADIAZOLO(4,3 A)QUINOXALIN 1 ONE; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; BIOLOGICAL FACTOR; CALCIUM ACTIVATED POTASSIUM CHANNEL; ENDOTHELIUM DEPENDENT HYPERPOLARIZATION FACTOR; ENDOTHELIUM-DEPENDENT HYPERPOLARIZATION FACTOR; ENZYME INHIBITOR; NITRIC OXIDE SYNTHASE; OXADIAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIALYSIS; FEMALE; FOREARM; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; ORGAN DONOR; PRIORITY JOURNAL; TENSION; VASODILATATION; VEIN; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ACETYLCHOLINE; BIOLOGICAL FACTORS; ENZYME INHIBITORS; FEMALE; FOREARM; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; OXADIAZOLES; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; QUINOXALINES; VASODILATION; VASODILATOR AGENTS; VEINS;

EID: 0142105832     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200310000-00021     Document Type: Article

References (46)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
2. Kielstein JT, Böger RH, Bode-Böger SM, Schärfer J, Barbey M, Koch KM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10:594-600.
3. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62:2425-2430.
4. Goonasekera CDA, Rees DD, Woolard P, Prend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997; 15:901-909.
5. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension. Circulation 2000; 101:856-861.
6. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068-2074.
7. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99:1141-1146.
8. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, et al. Asymmetric dimethylarg nine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 2000; 20:1040-1046.
9. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2:997-1000.
10. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intraarterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7:193-194.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288:373-376.
12. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-526.
13. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, et al. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 1997; 12:2623-2628.
14. Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53:1068-1077.
15. Taylor SG, Weston AH. Endothelium-derived hyperpolarising factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988; 9:272-274.
16. Garland CJ, Plane F, Kemp BK, Cocks TM. Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends Pharmacol Sci 1995; 16:23-30.
17. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396:269-272.
18. Doughty JM, Plane F, Langton PD. Charybdotoxin and apamin block EDHF in rat mesenteric artery if selectively applied to the endothelium. Am J Physiol Heart Circ Physiol 1999; 276:H1107-H1112.
19. Scotland RS, Chauhan S, Vallance P, Ahluwalia A. An endothelium-derived hyperpolarizing factor-like factor moderates miogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. Hypertension 2001 ; 38:833-839.
20. Kooman JP, Wijnen JAG, Draaijer P, Van Bortel LMAB, Gladziwa U, Peltemburg HG, et al. Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis. Kidney Int 1992; 41: 1041-1048.
21. Medina P, Segarra G, Martinez-León JB, Vila JM, Aldasoro M, Otero E, et al. Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann Thorac Surg 2000; 70:1327-1331.
22. Passauer J, Bussemaker E, Range U, Plug M, Gross P. Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium-dependent vasodilation in normotensive patients on chronic hemodialysis. J Am Soc Nephrol 2000; 11:1726-1734.
23. Kooman JP, Daemen MJAP, Wijnen R, Verluyten-Goessens MJ, van Hooff JP, Leunissen KML. Morphological changes of the venous system in uremic patients. A histopathologic study. Nephron 1995; 69:454-458.
24. Feinfeld DA, Batista R, Rabia M, Babich D. Changes in venous histology in chronic hemodialysis patients. Am J Kidney Dis 1999; 34:702-705.
25. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988; 93:515-524.
26. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest 1997; 100:2793-2799.
27. + channels. Circulation 1999; 99: 3132-3138.
28. Katz SD, Krum H. Acetylcholine-mediated vasodilation in the forearm circulation of patients with heart failure: indirect evidence for the role of endothelium-derived hyperpolarizing factor. Am J Cardiol 2001; 87:1089-1092.
29. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor. Identification and mechanisms of action in human subcutaneous resistance arteries. Circulation 2001; 103: 1702-1708.
30. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996; 78:415-423.
31. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 401:493-497.
32. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000; 106:1521-1530.
33. Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 2002; 290:909-913.
34. Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Goto M, et al. Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo. Circulation 2003; 107:1040-1045.
35. Randall MD, Alexander SP, Bennet T, Boyd EA, Fry JR, Gardiner SM, et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 1996; 229:114-120.
36. Chauhan SD, Nilsson H, Ahluwalia A, Hobbs AJ. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003; 100:1426-1431.
37. Campbell WB, Harder DR. Prologue: EDHF - what is it? Am J Physiol Heart Circ Physiol 2001; 280:H2413-H2416.
38. Ca channels. Circulation 2003; 107:769-776.
39. Sobey CG. Potassium channel function in vascular disease. Arterioscler Thromb Vasc Biol 2001; 21:28-38.
40. Joannides R, Richard V, Haefeli WE, Benoist A, Linder L, Luscher TF, et al. Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension 1997; 30: 1465-1470.
41. Kilpatrick EV, Cocks TM. Evidence for differential roles of nitric oxide (NO) and hyperpolarization in endothelium-dependent relaxation of pig isolated coronary artery. Br J Pharmacol 1994; 112:557-565.
42. Brandes RP, Behra A, Lebherz C, Boger RH, Bode-Boger SM, Phivthong-Ngam L, et al. N(G)-nitro-L-arginine- and indomethacin-resistant endothelium- dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis 1997; 135:49-55.
43. Petersson J, Zygmunt PM, Hogestatt ED. Characterization of the potassium channels involved in EDHF-mediated relaxation in cerebral arteries. Br J Pharmacol 1997; 120:1344-1350.
44. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol Heart Circ Physiol 1986; 250:H1145-H1149.
45. Blackman DJ, Morris-Thurgood JA, Atherton JJ, Ellis GR, Anderson RA, Cockcroft JR, et al. Endothelium-derived nitric oxide contributes to regulation of venous tone in humans. Circulation 2000; 101:165-170.
46. Halcox JP, Narayanan S, Cramer-Joyce L, Mincemoyer R, Quyyumi AA. Characterization of endothelium-derived hyperpolarizing factor in human forearm microcirculation. Am J Physiol Heart Circ Physiol 2001; 280:H2470-H2477.